Rethinking Mitral Regurgitation in Hypertrophic Cardiomyopathy: Prognostic Impact Varies Significantly by Subtype

Introduction

The clinical landscape of hypertrophic cardiomyopathy (HCM) is characterized by its remarkable heterogeneity, ranging from asymptomatic presentations to sudden cardiac death and progressive heart failure. Among the various comorbidities associated with HCM, mitral regurgitation (MR) is one of the most prevalent and clinically challenging. Traditionally, MR in HCM has been viewed through the lens of left ventricular outflow tract (LVOT) obstruction, where systolic anterior motion (SAM) of the mitral valve leads to dynamic regurgitation. However, as our understanding of HCM phenotypes expands to include non-obstructive, midventricular, and end-stage forms, the assumption that MR carries a uniform prognostic weight has come under scrutiny. The REVEAL-HCM study provides a critical, multicenter look at how MR impacts long-term outcomes across different HCM subtypes, challenging existing management paradigms.

Disease Burden and Clinical Context

Hypertrophic cardiomyopathy affects approximately 1 in 500 individuals globally and remains a leading cause of heart failure and sudden death in young adults. Mitral regurgitation is found in a significant proportion of these patients, but its pathophysiology varies. In hypertrophic obstructive cardiomyopathy (HOCM), MR is often dynamic and secondary to the Venturi effect pulling the mitral leaflets into the outflow tract. In contrast, in non-obstructive or end-stage HCM (ES-HCM), MR may result from ventricular remodeling, annular dilatation, or intrinsic valve abnormalities. Despite its frequency, clinicians have lacked robust evidence regarding whether MR is a primary driver of poor outcomes or merely a marker of advanced myocardial disease. This gap in knowledge is particularly acute when deciding between aggressive valvular intervention and medical management.

Study Design and Methodology

The REVEAL-HCM study was a retrospective, multicenter registry conducted in Japan, designed to evaluate the prognostic implications of MR across the spectrum of HCM. Researchers included 3,602 patients, categorized into three distinct subtypes: 1) Hypertrophic Obstructive Cardiomyopathy (HOCM, n=837); 2) End-Stage HCM (ES-HCM, n=275); and 3) Other HCM (n=2,490), which included non-obstructive, midventricular, and apical HCM. The severity of MR was dichotomized into moderate or greater (moderate+) versus mild or less (mild-). The primary endpoint was a composite of all-cause death or heart failure (HF) hospitalization. The study utilized a median follow-up period of 5.3 years, allowing for a longitudinal assessment of both clinical outcomes and the temporal progression or regression of MR severity.

Key Findings: The Divergence of Prognosis

The prevalence of moderate+ MR varied significantly by subtype, being highest in HOCM (36.3%), followed by ES-HCM (21.5%), and other HCM (8.5%). However, the prognostic impact of this MR did not follow the same hierarchy.

HOCM and ES-HCM: A Surprising Lack of Association

In the HOCM group, the 5-year cumulative incidence of all-cause death or HF hospitalization was 14.6% for those with moderate+ MR compared to 12.4% for those with mild- MR. This difference was not statistically significant (P=0.35). Even after adjusting for clinical covariates, the hazard ratio (HR) remained non-significant at 1.13 (95% CI, 0.79-1.60). Similarly, in the ES-HCM group, where mortality rates were expectedly higher, MR severity did not differentiate outcomes (60.7% for moderate+ vs. 54.7% for mild-; HR 0.84, P=0.42). These findings suggest that in these specific subtypes, the underlying myocardial substrate and hemodynamic obstruction may play a more dominant role in determining prognosis than the MR itself.

The ‘Other’ HCM Subtype: A High-Risk Marker

The most striking results were observed in the ‘Other HCM’ group (non-obstructive, midventricular, and apical). In these patients, moderate+ MR was associated with a vastly higher 5-year incidence of the primary endpoint: 34.2% compared to only 13.9% in the mild- MR group (P<0.001). After multivariable adjustment, the association remained robust (HR 1.45; 95% CI, 1.09-1.91), with a significant interaction between HCM subtype and MR severity (P-interaction = 0.02).

Temporal Trends in MR Severity

The study also tracked how MR changed over time. In HOCM, MR severity frequently improved, likely reflecting the success of septal reduction therapies or medical management in reducing LVOT gradients and SAM. In ES-HCM, MR severity remained relatively stable, whereas in the ‘Other HCM’ group, MR severity tended to worsen over time (P<0.001). This progression in non-obstructive subtypes suggests a link between MR and progressive ventricular dysfunction or remodeling.

Expert Commentary and Clinical Implications

The REVEAL-HCM findings suggest a shift in how we interpret mitral regurgitation in the context of cardiomyopathy. In HOCM, MR is often a ‘symptom’ of the obstruction; once the obstruction is managed, the MR often regresses, which explains its lack of independent long-term prognostic weight in this study. However, in non-obstructive HCM, the presence of moderate+ MR appears to be a red flag for poor prognosis. In these patients, MR is likely not just a hemodynamic bystander but a contributor to volume overload and further myocardial stress.

Mechanistic Insights

The different trajectories of MR—improving in HOCM but worsening in non-obstructive types—highlight the underlying biological differences. In HOCM, MR is largely functional and dynamic. In non-obstructive types, MR might be more closely tied to ‘proliferative’ or ‘fibrotic’ remodeling of the valve and ventricle. This study underscores the need for HCM subtype-specific management. For a patient with HOCM and moderate MR, the focus remains on relieving obstruction. For a patient with non-obstructive HCM and moderate MR, more intensive monitoring for heart failure and potentially earlier consideration of valve-specific or advanced HF therapies may be warranted.

Study Limitations

As a retrospective registry study, there are inherent limitations, including potential selection bias and variations in echocardiographic assessment across centers. Furthermore, the Japanese population studied may have different genetic backgrounds compared to Western cohorts, particularly regarding the prevalence of apical HCM. However, the large sample size and multicenter nature provide strong real-world evidence.

Summary and Conclusions

The REVEAL-HCM study provides a necessary refinement to our prognostic models for hypertrophic cardiomyopathy. It demonstrates that moderate or greater MR is not a universal predictor of mortality or heart failure across all HCM phenotypes. While it is most common in HOCM, its presence there does not independently worsen the 5-year prognosis, often because the MR is reversible or manageable through standard obstructive therapies. Conversely, in non-obstructive and other HCM subtypes, MR is a potent and independent predictor of adverse outcomes. Clinicians should use these findings to tailor their surveillance and intervention strategies, recognizing that the clinical meaning of a leaky mitral valve depends entirely on the ‘neighborhood’ of the heart in which it resides.

References

Obayashi Y, Kato T, Shiomi H, et al. Prognostic Implications of Mitral Regurgitation Across Hypertrophic Cardiomyopathy Subtypes: A Report From REVEAL-HCM Study. Circ Heart Fail. 2026 Feb 4:e013977. doi: 10.1161/CIRCHEARTFAILURE.125.013977.